Get the Stockscreener App
0.2706
3.02%
-0.0083
Allakos Inc stock is traded at $0.2706, with a volume of 1.92M.
It is down -3.02% in the last 24 hours and down -73.74% over the past month.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
See More
Previous Close:
$0.2789
Open:
$0.2752
24h Volume:
1.92M
Relative Volume:
0.99
Market Cap:
$24.92M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
-0.1409
EPS:
-1.92
Net Cash Flow:
$-139.92M
1W Performance:
+12.61%
1M Performance:
-73.74%
6M Performance:
-61.66%
1Y Performance:
-78.53%
1-Day Range:
$0.266
$0.2775
1-Week Range:
$0.228
$0.284
52-Week Range:
$0.228
$1.69
Allakos Inc Stock (ALLK) Company Profile
Name
Allakos Inc
Sector
Industry
Phone
650-597-5002
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Compare ALLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.2705 | 24.92M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-17-24 | Downgrade | Jefferies | Buy → Hold |
| Jan-16-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-18-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-08-23 | Resumed | Jefferies | Buy |
| Sep-27-23 | Initiated | JMP Securities | Mkt Outperform |
| May-12-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-07-23 | Initiated | Piper Sandler | Overweight |
| Sep-12-22 | Downgrade | SMBC Nikko | Neutral → Underperform |
| Dec-22-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-21 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-22-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-22-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-15-21 | Initiated | Cowen | Outperform |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Feb-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | BofA Securities | Buy |
| Dec-21-20 | Initiated | SVB Leerink | Outperform |
| Feb-27-20 | Initiated | Barclays | Underweight |
| Feb-04-20 | Resumed | Goldman | Neutral |
| Aug-13-18 | Initiated | Goldman | Neutral |
| Aug-13-18 | Initiated | Jefferies | Buy |
| Aug-13-18 | Initiated | William Blair | Outperform |
View All
Allakos Inc Stock (ALLK) Latest News
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Allakos stock tanks after company announces mass layoffs - MSN
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com
The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News
Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Allakos stock tumbles following AK006 trial discontinuation - MSN
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
Allakos to cease AK006 development after trial setback - MSN
Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena
Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Canada
Allakos shares fall as Jefferies cuts price target to $0.40 By Investing.com - Investing.com Nigeria
Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter
Allakos shares fall as Jefferies cuts price target to $0.40 - MSN
Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Bay Area biotech firm suddenly on brink of collapse after trial flops - SFGATE
Allakos Restructures Amid AK006 Program Discontinuation - TipRanks
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn
Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies - StreetInsider.com
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Allakos stock tumbles following AK006 trial discontinuation By Investing.com - Investing.com Australia
Allakos Drops AK006, Cuts 75% of Staff After Study Failure - MarketWatch
Allakos Restructures Amid AK006 Discontinuation and Layoffs - TipRanks
Allakos Inc Stock (ALLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):